AI Stock Analysis - Tscan Therapeutics (TCRX)
Analysis generated December 31, 2025.
TScan Therapeutics focuses on innovative T-cell receptor (TCR)-based therapies for cancer treatment. Their mission is to leverage their TCR platform to identify and develop novel cancer immunotherapies. Despite recent challenges, TScan continues to foster scientific research and development in hopes of groundbreaking therapeutic solutions for patients suffering from various cancers.
Stock Alerts - Tscan Therapeutics (TCRX)
 |
Tscan Therapeutics | March 9 Price is up by 6.3% in the last 24h. |
|
Tscan Therapeutics | March 5 Price is up by 7.4% in the last 24h. |
|
Tscan Therapeutics | February 27 Price is down by -6.3% in the last 24h. |
|
Tscan Therapeutics | February 25 Price is up by 6.7% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Tscan Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 856 | Sign up | Sign up | Sign up |
| X Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Tscan Therapeutics
None
| Price | $1.13 |
| Target Price | Sign up |
| Volume | 1,351,517 |
| Market Cap | $67M |
| Year Range | $0.9 - $2.52 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5March 4 - Benzinga |
|
 |
Earnings Breakdown: TScan Therapeutics Q4March 3 - Benzinga |
TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027March 3 - Benzinga |
|
TScan Therapeutics Q4 2025 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M EstimateMarch 3 - Benzinga |
|
TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M EstimateMarch 3 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -36M | -34M | -0.280 |
| Q2 '25 | 3.1M | 0 | 3.1M | -37M | -36M | -0.280 |
| Q1 '25 | 2.2M | 0 | 2.2M | -34M | -33M | -0.600 |
| Q4 '24 | 670,000 | 710,000 | 670,000 | -36M | -34M | -0.300 |
| Q3 '24 | 1M | 1M | 1M | -30M | -28M | -0.250 |
Insider Transactions View All
| Nichols Weston filed to buy 8,019,148 shares at $0.9. December 23 '25 |
| Nichols Weston filed to buy 8,012,916 shares at $0.9. December 23 '25 |
| Nichols Weston filed to buy 7,937,416 shares at $0.9. December 23 '25 |
| Nichols Weston filed to buy 7,946,141 shares at $1.2. May 21 '25 |
| Nichols Weston filed to buy 6,746,141 shares at $1.2. May 21 '25 |
Similar companies
Read more about Tscan Therapeutics (TCRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Tscan Therapeutics
The Market Cap of Tscan Therapeutics is $67M.
Currently, the price of one share of Tscan Therapeutics stock is $1.13.
The TCRX stock price chart above provides a comprehensive visual representation of Tscan Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tscan Therapeutics shares. Our platform offers an up-to-date TCRX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Tscan Therapeutics (TCRX) does not offer dividends to its shareholders. Investors interested in Tscan Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Tscan Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
